MT-TN

Chr MT

tRNA-Asn

Also known as: MTTN

Predicted to enable triplet codon-amino acid adaptor activity. Predicted to be involved in translation. [provided by Alliance of Genome Resources, Jul 2025]

ResearchGenerating clinical summary…

Clinical highlights

Gene-disease validity (ClinGen)
mitochondrial disease · MTDefinitivesufficient evidence for diagnostic panels
12
Active trials
1
Pubs (1 yr)
P/LP submissions
P/LP missense
LOEUF
Mechanism
Some data sources returned errors (1)

omim: Error: OMIM fetch failed: 429

Population Genetics & Constraint

Constraint data not available from gnomAD.

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

MT-TN · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

ACTIVE NOT RECRUITING
NCT04266249Phase PHASE2ECOG-ACRIN Cancer Research GroupStarted 2020-03-13
DocetaxelLumpectomyMastectomy
Fabry Disease

Fabry Disease Registry & Pregnancy Sub-registry

RECRUITING
NCT00196742Genzyme, a Sanofi CompanyStarted 2001-07-31
Advanced Pancreatic CarcinomaMetastatic Pancreatic CarcinomaStage II Pancreatic Cancer AJCC v8

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

RECRUITING
NCT06906562Phase PHASE2Sameek RoychowdhuryStarted 2025-08-26
PemigatinibComputed Tomography (CT)Magnetic Resonance Imaging
Stage II Colorectal Cancer AJCC v8Stage III Colorectal Cancer AJCC v8

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

ACTIVE NOT RECRUITING
NCT04137107Phase PHASE2, PHASE3Alliance for Clinical Trials in OncologyStarted 2020-06-17
OxaliplatinDuloxetine HydrochlorideDuloxetine
Multiple Myeloma

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

ACTIVE NOT RECRUITING
NCT04071457Phase PHASE3SWOG Cancer Research NetworkStarted 2019-08-13
LenalidomideDaratumumab/rHuPH20
Plasma Cell Myeloma

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

ACTIVE NOT RECRUITING
NCT01863550Phase PHASE3ECOG-ACRIN Cancer Research GroupStarted 2013-12-06
BortezomibCarfilzomibDexamethasone
Intracranial MeningiomaRecurrent MeningiomaNF2 Gene Mutation

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

RECRUITING
NCT02523014Phase PHASE2Alliance for Clinical Trials in OncologyStarted 2015-09-28
VismodegibFAK Inhibitor GSK2256098Capivasertib
Stage II Breast CancerStage IIIA Breast Cancer

Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

ACTIVE NOT RECRUITING
NCT01901094Phase PHASE3Alliance for Clinical Trials in OncologyStarted 2014-02-24
Axillary Lymph Node Dissection (ALND)Nodal Radiation TherapyAxillary Radiation Therapy
Breast Ductal Carcinoma In SituInvasive Breast CarcinomaStage II Breast Cancer AJCC v6 and v7

Breast Cancer WEight Loss Study (BWEL Study)

ACTIVE NOT RECRUITING
NCT02750826Phase PHASE3Alliance for Clinical Trials in OncologyStarted 2016-09-16
Health Education ProgramWeight Loss Intervention
DS Stage I Multiple MyelomaDS Stage II Multiple MyelomaDS Stage III Multiple Myeloma

Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

ACTIVE NOT RECRUITING
NCT00644228Phase PHASE3National Cancer Institute (NCI)Started 2008-07-28
BortezomibDexamethasoneLaboratory Biomarker Analysis
Metastatic Colon AdenocarcinomaMetastatic Rectal AdenocarcinomaStage III Colon Cancer AJCC v8

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

ACTIVE NOT RECRUITING
NCT05308446Phase PHASE2National Cancer Institute (NCI)Started 2022-07-19
CetuximabEncorafenibNivolumab
Cancer, MetastaticCancerCancer of Pancreas

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

RECRUITING
NCT03452774Massive Bio, Inc.Started 2018-01-01
Clinical Trial Matching